Enovis Corporation
ENOV Healthcare Medical Devices
Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024. In the quarter to June 2026, revenue grew 3.23%, EPS grew 96.9%, free cash flow grew 815.8% and total debt fell 7.82%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ENOV
Enovis Corporation (ENOV) EV/Sales
As of 16 October 2026, Enovis Corporation (ENOV) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from 0.7× (December 2015) to 13.3× (November 2021); the current reading is higher than 14% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.2× | (29.68%) |
| FY2024 | 1.8× | (13.52%) |
| FY2023 | 2.0× | 0.09% |
| FY2022 | 2.0× | (46.85%) |
| FY2021 | 3.8× | (16.56%) |
| FY2020 | 4.6× | 202.81% |
| FY2019 | 1.5× | 29.50% |
| FY2018 | 1.2× | (34.67%) |
| FY2017 | 1.8× | 54.61% |
| FY2016 | 1.2× | 37.82% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.1× | (5.85%) |
| Mar 2026 | 1.1× | (7.86%) |
| Dec 2025 | 1.2× | (9.74%) |
| Sep 2025 | 1.4× | (4.48%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.0× |
| ENOV Enovis Corporation | 1.0× |
| TNDM Tandem Diabetes Care, Inc. compare | 1.2× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| BVS Bioventus Inc. compare | 1.9× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.5× |
| AORT Artivion, Inc. compare | 2.9× |
| CBLL CeriBell, Inc. compare | 8.3× |
| IRMD iRadimed Corporation compare | 12.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)